Read the newsletter by clicking here
In 2017, Xintela took numerous steps that enabled the company to grow into a prominent player in the field of regenerative medicine, including building its own GMP facility for stem cell production. We also broadened our product options within the cancer project by licensing human antibodies that bind to our integrin markers.
Construction of our GMP facility for stem cell production dominated the first few months of 2018. Work is progressing according to plan. The offices and clean room will soon be finished and ready to be equipped with bio reactors and other critical production equipment. In connection with this, Xintela will move into new offices directly adjacent to the GMP facility. Our GMP lab is designed to produce cells for clinical trials and is prepared for expansion.
Xintela’s decision to build its own GMP facility for stem cell production was a strategically vital step. It gives Xintela a unique and strong position in the field of stem cells and has already attracted a great deal of attention in discussions with potential partners. It is also very satisfying that we already have functioning upscaled methods for producing stem cells from both horses and humans, ensuring that we will have GMP-certified production before the end of the year.
Xintela has also made good progress in its cancer project for treating the severe form of brain cancer known as glioblastoma. We are currently preparing to publish the project findings in order to further spread Xintela’s work within the field. We are also highly active in partnering conferences and have identified several potential partners. It is particularly gratifying that we were able to present, in December, an agreement to license human antibodies that bind to Xintela’s markers integrin α10β1 and integrin α11β1 and which can be used to further develop new products in cancer therapy and diagnostics.
Among other topics, you can read about our exciting partnership with Japanese CellSeed and licensing of antibodies for cancer projects in this newsletter. We also highlight one example of Japan’s dynamic cell therapy market, where a recent bid on one of Europe´s leading cell therapy companies demonstrates the robust economic potential and increased willingness to pay by major players in the field of regenerative medicine.
CEO, Xintela AB
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO